Item 1.01 Entry into a Material Definitive Agreement.

On September 29, 2012, GenVec, Inc. (the "Company") entered into an agreement with the U.S. Naval Medical Logistics Command to support malaria vaccine development efforts at the U.S. Naval Medical Research Center ("NMRC"). Under the Agreement, the Company will provide clinical supplies to be used in one or more Phase 1 clinical trials by the NMRC. Subject to the terms of the agreement, including the Navy's customary right of termination for convenience, the Company anticipates receiving approximately $3.5 million over three years, with approximately $0.6 million being recognized in the fourth quarter of 2012, $1.9 million being recognized in 2013, $1.0 million being recognized in 2014 and approximately $25,000 being recognized in 2015. The agreement contains an option of up to an additional $0.2 million of work that can be requested by the NMRC.

Item 7.01 Regulation FD Disclosure.

A copy of the press release regarding the announcement of the agreement described above is attached hereto and incorporated herein by reference as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number Description
99.1 Press release of GenVec, Inc., dated October 2, 2012